Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Dear Editor, We wish to clarify differences between figure 3 of the main manuscript (Body weight change from baseline at week 12) and table S3 (Summary of pharmacodynamic parameters at baseline and week 12)—specifically that the least squares mean (LSM) change from baseline body weight values shown in figure 3 are different than the implied weight change values indicated in table S3 across all orforglipron doses, when subtracting the LSM of body weight at baseline and week 12.1 We can clarify that the differences between the values shown in figure 3 and table S3 are because of the differences in the analysis model. The LSMs presented in figure 3 reflect the analysis from a linear mixed model with change from baseline as the response, while table S3 represents data from a model with actual values at week 12 as the response. For the change from baseline analysis, an unstructured covariance structure was used (figure 3), while for the actual weight values (table S3), there were model convergence issues when the same covariance structure was attempted and, therefore, a compound symmetry covariance structure was applied. With this subtle difference, the treatment differences are slightly different between the two analyses. The study pre-specified analysis for the treatment comparison is based upon the change from baseline (figure 3), and thus it is recommended that readers use this for interpreting the treatment effects. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15372.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15150 · Cited by 60
Self-citation
Cited by
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
Self-citationGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01554-1 · Cited by 38
Self-citationDutta, D., Nagendra, L., Anne, B., Kumar, M., Sharma, M., & Kamrul‐Hasan, A. B. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.743 · Cited by 35
Metadata
- Authors
- Pratt, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-11-23
- Volume
- 26
- Issue
- 3
- Pages
- 1137-1137
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4388976659
- Cited by
- 18
- References
- 1
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.15372
- The paper
- Pratt, E. (2024). Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.